UCB Förvaltning
Förvaltning kriterier kontrolleras 2/4
Vi har för närvarande inte tillräcklig information om VD:n.
Viktig information
Jean-Christophe Tellier
Verkställande direktör
€12.4m
Total ersättning
| VD-lön i procent | 11.26% |
| Anställning som VD | 11.3yrs |
| Ägande av VD | n/a |
| Ledningens genomsnittliga anställningstid | 5.8yrs |
| Styrelsens genomsnittliga mandatperiod | 12yrs |
Senaste uppdateringar av ledningen
Recent updates
UCB: Epilepsy And Neuroscience Execution Will Shape Balanced Risk Reward Profile
Analysts have adjusted the UCB price target toward €285, reflecting a blend of more cautious views that see risk and reward as balanced around €260 and more optimistic calls pointing toward €304 to €340, supported by expectations for its epilepsy portfolio and broader neuroscience exposure. Analyst Commentary Bullish Takeaways Bullish analysts see upside toward €304 to €340, suggesting that current pricing does not fully reflect expectations around the epilepsy portfolio and broader neuroscience pipeline.UCB: Epilepsy Franchise And Dermatology Data Will Shape Future Risk Reward Balance
Narrative Update on UCB The analyst price target for UCB has been adjusted slightly lower to about €285. This reflects a blend of more cautious views that see a balanced risk and reward at current levels, and more optimistic targets that highlight UCB's epilepsy portfolio and recent upward revisions from several banks.UCB: Epilepsy And Psoriatic Arthritis Execution Will Shape Future Risk Reward Balance
The updated analyst price target for UCB moves to €284.85 from €275.74. This reflects a mix of more conservative revenue growth assumptions, higher expected profit margins, and a lower future P/E multiple, in line with recent research that balances enthusiasm around epilepsy assets with a more measured view on risk and reward.
UCB: Epilepsy Franchise Expectations Will Eventually Strain Current Share Price
We are lifting our fair value estimate for UCB from €173.07 to €209.22, reflecting higher assumed revenue growth and profit margins as analysts highlight a stronger outlook for the epilepsy franchise and raise price targets into the €300+ range. Analyst Commentary Recent Street research on UCB has centered on the epilepsy franchise and the broader neuroscience portfolio, with several firms updating their views and price targets.UCB: Epilepsy Pipeline Progress And Execution Will Shape Future Upside Balance
Our Analyst Price Target for UCB has moved higher from €261.42 to €275.74, reflecting analysts' updated assumptions on revenue growth, profitability and P/E in light of recent Street target lifts to around €304 to €310. Analyst Commentary Recent Street research on UCB has centered on higher price targets, with bullish analysts adjusting their views to reflect updated assumptions on revenue, profitability and P/E.
UCB: Future Earnings Power To Reflect Rare Disease And Epilepsy Execution
Analysts have raised their price target on UCB to €310 from €270, citing updated assumptions for revenue growth, profit margins and a slightly lower future P/E multiple as the main drivers of the change. Analyst Commentary Recent commentary from bullish analysts has centered on higher valuation support for UCB, with the new €310 price target used as a reference point for what they see as stronger execution and earnings potential than previously modeled.UCB: Late-Stage Pipeline And Margin Execution Will Shape Balanced Upside Potential
Analysts raised their price target on UCB to €310 from €270, citing updated expectations for slightly stronger revenue growth, improved profit margins, and a modestly lower future P/E multiple. Analyst Commentary Bullish Takeaways Bullish analysts point to the higher €310 target as a sign that they see current valuation as not fully reflecting updated revenue and margin expectations.UCB: Raising Future Fair Value On Strengthening Rare Disease And Epilepsy Franchise
Analysts have raised their fair value estimate for UCB from €255 to €310, citing recent price target increases from the Street and updated assumptions on revenue growth, profit margins and future P/E levels. Analyst Commentary Bullish analysts have recently adjusted their views on UCB, with fresh price targets that now cluster around €290 to €310.UCB: Expanding Late-Stage Pipeline And New Launches Will Drive Future Upside
UCB's analyst price target has been raised from EUR 258.33 to EUR 264.67 as analysts factor in slightly stronger revenue growth expectations, despite a modestly lower projected profit margin and only a small uptick in future valuation multiples. Analyst Commentary Recent price target increases signal that bullish analysts see a more attractive risk reward profile for UCB, driven by improving growth visibility and confidence in execution.UCB: Pipeline Execution And New Launches Will Support Balanced Future Upside Potential
UCB's fair value estimate has been nudged higher to approximately EUR 258 from EUR 257, reflecting analysts' upward revisions to price targets, with recent moves to EUR 240, EUR 285 and EUR 290. These changes highlight confidence in the company's earnings trajectory despite slightly softer margin and growth assumptions.UCB: Recent Pipeline Advances And Margin Strength Will Drive Share Price Higher
Analysts have slightly raised their fair value estimate for UCB to €256.67. They cite recent upward revisions to price targets, supported by continued expectations for stable profit margins and healthy revenue growth.UCB (EBR:UCB) Could Easily Take On More Debt
Nov 11
UCB: Strong Profit Margins And Momentum Will Drive Shares Higher
UCB's fair value estimate has increased by approximately EUR 4.50, as analysts highlight robust performance and upward revisions to price targets. This follows renewed confidence in the company’s profit margin outlook.Analysts Raise UCB Price Targets Amid Positive Sector Outlook and Improved Growth Forecasts
UCB's analyst price target has been raised from €240.28 to €251.11, as analysts cite upward revisions to revenue growth forecasts along with an improved sector outlook. Analyst Commentary Recent analyst actions reflect a strongly positive sentiment toward UCB's outlook, as multiple firms have revised their price targets upward and maintained favorable ratings.Market Participants Recognise UCB SA's (EBR:UCB) Earnings Pushing Shares 25% Higher
Oct 14Aging Populations And Emerging Markets Will Unlock Opportunity
UCB's analyst price target has been increased from €229.06 to €240.28. This change reflects improved revenue growth expectations and profit margins highlighted by recent analyst updates.Aging Populations And Emerging Markets Will Unlock Opportunity
The slight increase in UCB’s consensus price target to €229.06 reflects improved revenue growth forecasts, while profit margin expectations remain stable. What's in the News Three-year data from BE HEARD trials show sustained efficacy and quality of life improvements with BIMZELX® in moderate-to-severe hidradenitis suppurativa, with better outcomes linked to earlier treatment.Aging Populations And Emerging Markets Will Unlock Opportunity
Analysts have raised their price target for UCB to €223.17, citing robust fundamentals, resilient earnings growth, and improved confidence in management despite recent share price weakness. Analyst Commentary Recent share price pullback seen as disconnected from underlying business strength.UCB SA (EBR:UCB) Not Lagging Market On Growth Or Pricing
Jul 17
BIMZELX's Successful Launch Will Expand Future Market Opportunities In Dermatology And Rheumatology
UCB's new product launches and high R&D success rate are driving anticipated revenue and margin growth across global markets.Analys av ersättningar till VD
| Datum | Total ersättning | Lön | Företagets resultat |
|---|---|---|---|
| Dec 31 2025 | €12m | €1m | €2b |
| Sep 30 2025 | n/a | n/a | €1b |
| Jun 30 2025 | n/a | n/a | €1b |
| Mar 31 2025 | n/a | n/a | €1b |
| Dec 31 2024 | €7m | €1m | €1b |
| Sep 30 2024 | n/a | n/a | €653m |
| Jun 30 2024 | n/a | n/a | €240m |
| Mar 31 2024 | n/a | n/a | €292m |
| Dec 31 2023 | €7m | €1m | €343m |
| Jun 30 2023 | n/a | n/a | €332m |
| Mar 31 2023 | n/a | n/a | €376m |
| Dec 31 2022 | €6m | €1m | €420m |
| Jun 30 2022 | n/a | n/a | €887m |
| Mar 31 2022 | n/a | n/a | €971m |
| Dec 31 2021 | €6m | €1m | €1b |
| Sep 30 2021 | n/a | n/a | €996m |
| Jun 30 2021 | n/a | n/a | €936m |
| Mar 31 2021 | n/a | n/a | €834m |
| Dec 31 2020 | €7m | €1m | €732m |
| Jun 30 2020 | n/a | n/a | €743m |
| Mar 31 2020 | n/a | n/a | €767m |
| Dec 31 2019 | €87k | n/a | €790m |
Ersättning vs marknad: Jean-Christophe s total kompensation ($USD 14.52M ) är över genomsnittet för företag av liknande storlek på Belgian marknaden ($USD 2.87M ).
Ersättning vs inkomst: Ersättningen för Jean-Christophe har ökat med mer än 20 % det senaste året.
VD OCH KONCERNCHEF
Jean-Christophe Tellier (66 yo)
11.3yrs
Anställning
€12,434,367
Kompensation
Dr. Jean-Christophe Tellier is CEO & Executive Director of UCB SA from July 01, 2020. Dr. Tellier served as Executive Vice President and President of European Operations at Ucb S.A. Dr. Tellier served as P...
Ledningsgrupp
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| CEO & Executive Director | 11.3yrs | €12.43m | inga uppgifter | |
| Executive VP & CFO | 5.8yrs | inga uppgifter | inga uppgifter | |
| Executive VP & Chief Scientific Officer | 1.9yrs | inga uppgifter | inga uppgifter | |
| Executive VP & General Counsel | 3yrs | inga uppgifter | inga uppgifter | |
| Executive VP & Chief Human Resources Officer | 6.2yrs | inga uppgifter | inga uppgifter | |
| Executive Vice President of Patient Evidence | 11.2yrs | inga uppgifter | inga uppgifter | |
| Executive Vice President of Patient Supply | 2.3yrs | inga uppgifter | inga uppgifter | |
| Executive VP of Patient Impact & Chief Commercial Officer | 2yrs | inga uppgifter | inga uppgifter | |
| Chief Accounting Officer & Head of Group Finance | 13.1yrs | inga uppgifter | inga uppgifter | |
| Head of Global Corporate Communication | no data | inga uppgifter | inga uppgifter | |
| Head of Investor Relations | no data | inga uppgifter | inga uppgifter | |
| Head of Sustainability | no data | inga uppgifter | inga uppgifter |
5.8yrs
Genomsnittlig anställningstid
58.5yo
Genomsnittlig ålder
Erfaren ledning: UCB s ledningsgrupp är erfaren och erfaren ( 5.8 års genomsnittlig anställning).
Styrelseledamöter
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| CEO & Executive Director | 12yrs | €12.43m | inga uppgifter | |
| Honorary Chairman | no data | €70.00k | inga uppgifter | |
| Honorary Chairman | 21.3yrs | €15.50k | inga uppgifter | |
| Honorary Deputy Chairman | no data | €28.50k | inga uppgifter | |
| Honorary Chairman | no data | €30.00k | inga uppgifter | |
| Honorary Chairman | 5yrs | €87.50k | inga uppgifter | |
| Honorary Chairman | no data | €49.00k | inga uppgifter | |
| Independent Director | 12yrs | €207.83k | inga uppgifter | |
| Independent Chair of the Board | 5yrs | €438.33k | inga uppgifter | |
| Vice-Chair of the Board | 14yrs | €192.33k | inga uppgifter | |
| Independent Director | 2.3yrs | €180.33k | inga uppgifter | |
| Director | 12yrs | €157.83k | inga uppgifter |
12.0yrs
Genomsnittlig anställningstid
74yo
Genomsnittlig ålder
Erfaren styrelse: UCB s styrelse är rutinerade och erfaren ( 12 års genomsnittlig mandatperiod).
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/04/29 12:09 |
| Aktiekurs vid dagens slut | 2026/04/29 00:00 |
| Intäkter | 2025/12/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
UCB SA bevakas av 38 analytiker. 17 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Brian Bourdot | Barclays |
| Charles Pitman | Barclays |
| Charles Pitman | Barclays |